FLT3 and acute myeloid leukemia: In a real-world study of treatment practices and clinical outcomes among Australian patients (n = 73) with newly diagnosed FLT3 mutation-positive AML in the pre-midostaurin era, the study population was broadly similar to that of our study in terms of adverse cytogenetic risk (7%) and NPM1 co-mutation positivity (60%) [27].